Skip to content

Randomised controlled trial for evaluating the prescribing impact of information meetings led by pharmacists and of new information formats in General Practice in Italy: INFANT 2

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN28525676
Enrollment
900
Registered
2007-06-07
Start date
2007-03-15
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Information to physicians Not Applicable Physician training

Interventions

Three groups of single physicians will be provided with one of the following: 1. One information meeting led by a pharmacist and supported by a bulletin developed ad hoc 2. One information meeting led

Sponsors

Italian Drug Agency (Agenzia Italiana del Farmaco [AIFA])
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All GPs are eligible, provided that their Local Health Authority has an organised system for tracking their prescriptions made within the Italian National Heath Service (NHS) till the 5th Anatomic Therapeutic Chemical (ATC) level, in order to evaluate these prescriptions and to provide doctors with feedback.

Exclusion criteria

Exclusion criteria: No exclusion criteria.

Design outcomes

Primary

MeasureTime frame
Difference (%) in NHS prescription of drugs under scrutiny (expressed as Defined Daily Dose [DDD] per thousand inhabitants/day), comparing those who have/ have not received the specific information. Prescriptions within six months after the intervention will be evaluated.

Secondary

MeasureTime frame
1. Difference in the % of patients who were prescribed the specific drug(s) 2. Difference in the % of patients who were prescribed the specific drug(s) for the first time (in the previous 12 months) 3. Difference in expenditure for the specific drug (per 1000 patients/day) 4. Difference in NHS prescription of drugs under scrutiny (expressed as DDD per thousand inhabitants/day), comparing those who have received the ?traditional? versus ?enriched? format, and any information versus no information 5. Differences in the main and secondary outcomes according to the number of assisted population in the related PCG 6. Adjusted difference in prescribed DDD per 1000 patients/day according to a statistical model, considering as possible covariates: 6.1. Overall prescription in DDD per 1000 patients day at baseline 6.2. Number of assisted population 6.3. Geographical location (mountain, hill, plain, urban centre ? according to definitions given by the Italian Statistics Institute) 6.4. Age distribution of assisted population (in quartiles) 6.5. % females in the assisted population 6.6. Physician age 6.7. Total physician drug expenditure (excluding drugs under scrutiny) 6.8. % assisted population with polyprescription (greater than or equal to three drugs of different classes) 6.9. Number of new prescriptions (in the last 12 months) 6.10. Month of evaluation 6.11. Participation to the information meetings 6.12. % exact answers to the questionnaire testing knowledge 7. Difference in knowledge (measured through the number of correct answers to a specific questionnaire) 8. Difference in attitudes (measured through the answers to a specific anonymous questionnaire) Prescriptions within six months after the intervention will be evaluated.

Countries

Italy

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Apr 6, 2026